NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts ...

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. Companies specializing in drug ...

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

On March 3, FTRE released Q4 2024 earnings. The stock dropped from $13.86 to $11.00 as the company missed both revenues and EPS. Most of the shortfall was due to extra spin-off costs and the ...

Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently ...

FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...

(FTRE) came out with quarterly earnings of $0. ... The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly ...